NCT01457144 - Study of Mantle Cell Lymphoma Treatment by RiBVD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

March 31, 2016

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

RiBVD

"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"

Trial Locations (1)

38043

Valerie ROLLAND NEYRET, Grenoble